U.S. markets close in 2 hours 51 minutes
  • S&P 500

    4,136.99
    -27.01 (-0.65%)
     
  • Dow 30

    34,094.22
    -62.47 (-0.18%)
     
  • Nasdaq

    11,980.01
    -133.78 (-1.10%)
     
  • Russell 2000

    1,950.12
    -22.49 (-1.14%)
     
  • Crude Oil

    78.09
    +0.95 (+1.23%)
     
  • Gold

    1,887.70
    +2.90 (+0.15%)
     
  • Silver

    22.39
    +0.21 (+0.96%)
     
  • EUR/USD

    1.0741
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    3.6580
    -0.0160 (-0.44%)
     
  • GBP/USD

    1.2095
    +0.0043 (+0.35%)
     
  • USD/JPY

    131.1290
    +0.0570 (+0.04%)
     
  • BTC-USD

    23,020.13
    -273.05 (-1.17%)
     
  • CMC Crypto 200

    530.55
    -6.34 (-1.18%)
     
  • FTSE 100

    7,885.17
    +20.46 (+0.26%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

MacroGenics, Inc. (NASDAQ:MGNX) insider upped their holding by 26% earlier this year

Viewing insider transactions for MacroGenics, Inc.'s (NASDAQ:MGNX ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for MacroGenics

MacroGenics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Senior VP James Karrels for US$99k worth of shares, at about US$2.47 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$6.38. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

MacroGenics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does MacroGenics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. MacroGenics insiders own about US$11m worth of shares. That equates to 2.8% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About MacroGenics Insiders?

The fact that there have been no MacroGenics insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in MacroGenics and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 4 warning signs for MacroGenics (1 makes us a bit uncomfortable) you should be aware of.

But note: MacroGenics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here